Close Menu

NEW YORK – Shenzhen, China-based Snibe Diagnostic announced Friday it has received CE marking for its Maglumi 2019-nCoV (SARS-CoV-2) IgM/IgG kits, which are currently being used by hospitals in China and will soon be available to hospitals in Italy. The first batch of reagent kits were distributed to several key hospitals in China during the past few weeks, Snibe said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.